Table 1.
Baseline clinical characteristics of patients according to eGFR changes during follow-up.
| Characteristic | eGFR at the End of Follow-Up | p | |
|---|---|---|---|
| ≤90% of Initial Value (n = 30) | >90% of Initial Value (n = 79) | ||
| Mean age ± SD, years | 54 ± 14 | 54 ± 13 | 0.8 |
| Male sex, n (%) | 18 (60) | 48 (73) | 0.9 |
| Median time from transplantation (Q1; Q3), years | 8 (5; 14) | 7 (3; 13) | 0.5 |
| Primary cause of kidney disease | |||
| glomerular diseases, n (%) | 12 (40) | 27 (34) | 0.9 |
| tubulointerstitial diseases, n (%) | 4 (13) | 13 (16) | |
| vascular diseases, n (%) | 1 (3) | 5 (6) | |
| cystic/congenital diseases, n (%) | 3 (10) | 12 (15) | |
| unknown, n (%) | 10 (33) | 22 (28) | |
| First transplant, n (%) | 25 (83) | 72 (91) | 0.2 |
| Second transplant, n (%) | 5 (17) | 7 (9) | |
| Deceased donor, n (%) | 30 (100) | 78 (99) | 1.0 |
| Median number of HLA mismatches (Q1; Q3) * | 3 (2; 4) | 3 (3; 4) | 0.8 |
| Median peak pretransplant PRA (Q1; Q3), % * | 10 (0; 30) | 0 (0; 3) | 0.045 |
| Median last pretransplant PRA (Q1; Q3), % * | 0 (0; 10) | 0 (0; 0) | 0.1 |
| Induction therapy, n (%) | 3 (10) | 11 (19) | 0.9 |
| no data, n (%) | 13 (43) | 21 (27) | |
| Median cold ischemia time (Q1; Q3), min ** | 1320 (1170; 1566) | 1100 (840; 1470) | 0.06 |
| Median warm ischemia time (Q1; Q3), min ** | 35 (29; 50) | 32 (27; 40) | 0.3 |
| Delayed graft function, n (%) | 11 (37) | 21 (27) | 0.5 |
| no data, n (%) | 10 (33) | 19 (24) | |
| Immunosuppression | |||
| glucocorticoids, n (%) | 30 (100) | 76 (96) | 0.6 |
| MMF or MPA, n (%) | 28 (93) | 74 (94) | 0.9 |
| cyclosporine, n (%) | 7 (23) | 22 (28) | 0.6 |
| tacrolimus, n (%) | 21 (70) | 53 (67) | 0.8 |
| mTOR inhibitor, n (%) | 2 (7) | 5 (7) | 0.9 |
| Diabetes, n (%) | 8 (27) | 13 (16) | 0.2 |
| Hypoglycemic agents | |||
| oral, n (%) | 4 (13) | 9 (11) | 0.8 |
| insulin, n (%) | 4 (13) | 5 (6) | 0.2 |
| Use of RAA blockers, n (%) | 11 (37) | 35 (44) | 0.5 |
| Median daily diuresis (Q1; Q3), mL | 2500 (2000; 3000) | 2500 (2000; 3000) | 0.4 |
| Mean BMI ± SD, kg/m2 | 25 ± 5 | 27 ± 5 | 0.2 |
| Mean systolic pressure ± SD, mmHg | 138 ± 15 | 133 ± 13 | 0.1 |
| Mean diastolic pressure ± SD, mmHg | 84 ± 11 | 83 ± 10 | 0.9 |
* Available in 46 patients (14 with decreasing eGFR and 32 with non-decreasing eGFR) who underwent transplantation procedure in University Hospital, Kraków, Poland; ** Available in 80 patients (19 with decreasing eGFR and 61 with non-decreasing eGFR). BMI, body mass index; eGFR, estimated glomerular filtration rate; MMF, mycophenolate mofetil; MPA, mycophenolic acid; mTOR, mammalian target of rapamycin; PRA, panel reactive antibodies; Q1, first quartile; Q3, third quartile; RAA, renin-angiotensin-aldosterone system; SD, standard deviation.